Form 8-K - Current report:
SEC Accession No. 0001564590-21-056180
Filing Date
2021-11-10
Accepted
2021-11-10 16:07:39
Documents
14
Period of Report
2021-11-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K trvi-8k_20211110.htm   iXBRL 8-K 42928
2 EX-99.1 trvi-ex991_6.htm EX-99.1 134824
3 GRAPHIC gbpecyqoaeqe000001.jpg GRAPHIC 29443
  Complete submission text file 0001564590-21-056180.txt   361072

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA trvi-20211110.xsd EX-101.SCH 5721
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE trvi-20211110_lab.xml EX-101.LAB 20073
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE trvi-20211110_pre.xml EX-101.PRE 11961
7 EXTRACTED XBRL INSTANCE DOCUMENT trvi-8k_20211110_htm.xml XML 3685
Mailing Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510
Business Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510 203-304-2499
Trevi Therapeutics, Inc. (Filer) CIK: 0001563880 (see all company filings)

EIN.: 450834299 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38886 | Film No.: 211396589
SIC: 2834 Pharmaceutical Preparations